ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2014

Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab.

Philippe Bégin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.